Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vaxcyte Inc
(NQ:
PCVX
)
111.58
-0.52 (-0.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vaxcyte Inc
< Previous
1
2
3
4
Next >
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 06, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
September 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
September 03, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Peering Into Vaxcyte's Recent Short Interest
August 27, 2024
Via
Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 03, 2024
Via
Benzinga
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
September 03, 2024
Via
Benzinga
PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024
May 08, 2024
PCVX stock results show that Vaxcyte beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Recap: Vaxcyte Q4 Earnings
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
September 03, 2024
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's...
Via
Benzinga
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
September 03, 2024
The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market.
Via
Investor's Business Daily
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 03, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Appoints John Furey to Board of Directors
July 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
April 10, 2024
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the...
Via
Benzinga
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
March 12, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
March 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 15, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
February 01, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Pricing of $750 Million Public Offering
January 30, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 30, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
January 29, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Appoints Whitney Jones as Chief People Officer
January 16, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
January 05, 2024
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),
Via
Benzinga
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
January 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.